Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03985189
Recruitment Status : Active, not recruiting
First Posted : June 13, 2019
Last Update Posted : December 10, 2019
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma

Condition or disease Intervention/treatment Phase
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Drug: ME-401 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Japanese Phase 1 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Actual Study Start Date : April 29, 2019
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: ME-401
ME-401 administered orally
Drug: ME-401
ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.




Primary Outcome Measures :
  1. Number of participants with treatment-emergent adverse events (TEAEs) [ Time Frame: Up to approximately 1 year ]

Secondary Outcome Measures :
  1. Plasma concentration level of ME-401 [ Time Frame: Up to approximately 2 years ]
  2. Maximum plasma drug concentration (Cmax) [ Time Frame: Up to approximately 2 years ]
  3. Area under the plasma drug concentration time curve (AUC) [ Time Frame: Up to approximately 2 years ]
  4. Terminal half-life (t1/2) [ Time Frame: Up to approximately 2 years ]
  5. Efficacy of ME-401 as assessed by the objective response rate (ORR) [ Time Frame: Up to approximately 2 years ]
  6. Efficacy of ME-401 will be assessed by the duration of response (DOR) [ Time Frame: Up to approximately 2 years ]
  7. Efficacy of ME-401 will be assessed by the progression-free survival (PFS) [ Time Frame: Up to approximately 2 years ]
  8. Efficacy of ME-401 will be assessed by the time to response (TTR) [ Time Frame: Up to approximately 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 20 years or older at the submission of the written informed consent form
  • Patients with relapsed or refractory B-cell NHL
  • Patients who have not undergone phosphatidylinositol 3-kinase inhibitor (PI3K) to date.
  • Patients who have undergone Bruton's tyrosine kinase (BTK) inhibitors and have had no exacerbation during the use of BTK inhibitors.
  • Patients with ECOG PS 0 or 1.

Exclusion Criteria:

  • Patients who underwent any major surgical treatment within 4 weeks prior to the initiation of the investigational product.
  • Patients with poorly controlled diseases. The followings are the examples but the diseases will not be limited to those.
  • Patients in whom any of HBV antigen/antibody, HCV antibody, HIV antibody or HTLV-1 antibody will be positive at screening test.
  • Patients with active interstitial lung disease or a history thereof.
  • Patients who have received the investigational products other than ME-401, systemic chemotherapy or radiotherapy within 4 weeks prior to the initiation of ME-401.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03985189


Locations
Layout table for location information
Japan
The Cancer Institute Hospital of JFCR
Koto-Ku, Tokyo, Japan
Sponsors and Collaborators
Kyowa Kirin Co., Ltd.

Layout table for additonal information
Responsible Party: Kyowa Kirin Co., Ltd.
ClinicalTrials.gov Identifier: NCT03985189     History of Changes
Other Study ID Numbers: ME-401-K01
First Posted: June 13, 2019    Key Record Dates
Last Update Posted: December 10, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases